All In Biotech

Drug Trial Radar · NCT07930637

Rimonabant for Cognitive Impairment in People With Post-COVID-19 Syndrome

Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on the Improvement of Cognitive Impairment in Patients With Post-COVID-19 Syndrome (RIMOCOVID-1)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Nov 6, 2026

Primary completion

Mar 2028

Study completion Mar 2028

Sponsor

Lead sponsor
Sinfatin S.LIndustry
Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main goal of the study is to assess the effect of rimonabant in cognitive performance in patients with Post-COVID-19 Syndrome, also known as long COVID. The study will include 80 adults aged 18 to 75 years that will receive either rimonabant (5 mg) or placebo (a look-alike tablet that contains no drug) once daily for 90 days. Neither the participants nor the investigators will know which treatment is being given. The study will also help to learn about the safety of rimonabant.

Conditions

  • Post-COVID-19 Syndrome

Interventions

  • RimonabantDrug

    Rimonabant 2.5 mg tablets. Two tablets are taken together orally once a day in fasted conditions, providing a total daily dose of 5 mg. Treatment duration is 90 days.

  • PlaceboDrug

    Placebo tablets matching the appearance of the rimonabant tablets. Two tablets are taken together orally once daily in fasted conditions. Treatment duration is 90 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Symbol Digit Modalities Test (SDMT)Time frame: Baseline to end of follow-up (day 135)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario de Albacete

    Albacete, Spain

  • Hospital Clinica San Carlos HCSC

    Madrid, Spain

  • Hospital Nacional de Paraplejicos

    Toledo, Spain

  • Athenea Neuroclinics

    San Sebastián, Donostia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.